KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
KEYNOTE-022 第 3 部分:一项针对 BRAF 突变型黑色素瘤的帕博利珠单抗、达拉非尼和曲美替尼的随机、双盲、II 期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2020-001806
Ferrucci, Pier Francesco; Di Giacomo, Anna Maria; Del Vecchio, Michele; Atkinson, Victoria; Schmidt, Henrik; Schachter, Jacob; Queirolo, Paola; Long, Georgina V; Stephens, Rosalie; Svane, Inge Marie; Lotem, Michal; Abu-Amna, Mahmoud; Gasal, Eduard; Ghori, Razi; Diede, Scott J; Croydon, Elizabeth S; Ribas, Antoni; Ascierto, Paolo Antonio